Skip to main content
HLB bioStep Co.,Ltd. logo

HLB bioStep Co.,Ltd. — Investor Relations & Filings

Ticker · 278650 ISIN · KR7278650007 KO Professional, scientific and technical activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2020-03-20 Director's Dealing
Country KR South Korea
Listing KO 278650

About HLB bioStep Co.,Ltd.

http://hlbbiostep.com/en/

HLB bioStep Co.,Ltd. is a non-clinical Contract Research Organization (CRO) that provides a range of testing services to pharmaceutical companies and bio ventures. The company's core services support new drug development and include efficacy testing, pharmacokinetic/toxicokinetic (PK/TK) studies, and toxicology evaluations. A key area of specialization is veterinary medicine; HLB bioStep is an institution approved to conduct non-clinical tests and clinical trials for veterinary drugs. It also offers consulting services for regulatory approval procedures. The company utilizes various platform technologies, such as cell-enzyme-based screening and xenograft assays, and provides a comprehensive 'One-Stop Service' that leverages its experience in building laboratory facilities.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when company insiders (directors, executives, or major shareholders) trade company stock. This falls under the category of 'Director's Dealing' (DIRS) as it details personal share transactions by company executives.
2020-03-20 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing from a Korean company (Notus) regarding a correction to a previously submitted financial disclosure ('매출액 또는 손익구조 30% 이상 변동'). It provides a 'Before' and 'After' comparison of financial figures due to audit results. Since this is a specific regulatory filing for financial disclosure updates and does not fit into the other categories like 10-K or IR (which are full reports), it is classified as a Regulatory Filing (RNS). FY 2019
2020-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 96% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출). It provides the auditor's opinion (적정/Unqualified), financial highlights (assets, liabilities, equity, revenue, profit), and details regarding the audit process for the fiscal year. While it contains financial data, it is specifically an announcement of the receipt and submission of the audit report to the regulatory body, rather than the full annual report document itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2019
2020-03-19 Korean
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange. It specifically details a decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This falls under the category of a company buying back its own shares, which is classified as 'Transaction in Own Shares' (POS).
2020-03-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by the company 'Notus'. It outlines the date, location, and specific agenda items (such as financial statement approval, articles of incorporation amendments, and director/auditor compensation limits) to be voted on at the upcoming Annual General Meeting. This fits the definition of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on meeting agenda items.
2020-02-27 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings, citing scheduling constraints. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2020-02-27 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.